Javid’s decision to legalise medical cannabis in 2018 came after a long-running campaign waged by the parents of children diagnosed with severe epilepsy, who reported that cannabis oil helped with their condition. Celadon is one of the few firms that grow medical cannabis in the UK but, unlike others, uses an indoor lab rather than greenhouses. This means it can produce five to six harvests each year and a much higher yield, it says, although an indoor lab is more expensive to run. However, medical cannabis can only be prescribed by specialist doctors, patients often pay for it themselves, and it cannot be imported until a prescription has been issued, on a named-patient basis. James Short, the 54-year-old founder and chief executive of Celadon, was sceptical at first. “In early 2018, my son approached me and asked me did I want to invest in the medical cannabis sector?
Celadon is one of the few firms that grow medical cannabis in the UK but, unlike others, uses an indoor lab rather than greenhouses. This means it can produce five to six harvests each year and a much higher yield, it says, although an indoor lab is more expensive to run.
The company is following in the footsteps of GW Pharmaceuticals, a trailblazer that developed the first cannabis-based medicine to be licensed in the UK in 2010, Sativex for multiple sclerosis, which costs about £2,000 a year. However, NHS...
Read the full article @ Cannabis Law Report